We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

85 hedge funds and large institutions have $522M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

6% more funds holding

Funds holding: 8085 (+5)

0% more capital invested

Capital invested by funds: $522M → $522M (+$40.5K)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

96% less call options, than puts

Call options by funds: $778K | Put options by funds: $20.5M

Holders
85
Holders Change
+5
Holders Change %
+6.25%
% of All Funds
1.85%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
18
Increased
36
Reduced
17
Closed
11
Calls
$778K
Puts
$20.5M
Net Calls
-$19.7M
Net Calls Change
-$19.7M
Name Holding Trade Value Shares
Change
Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$341K +$122K +5,200 +53%
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
$320K +$332K +14,196 New
CSS
53
Cubist Systematic Strategies
Connecticut
$306K +$114K +4,854 +56%
VEA
54
Virtus ETF Advisers
New York
$281K +$43.8K +1,871 +18%
ProShare Advisors
55
ProShare Advisors
Maryland
$272K -$39.2K -1,674 -12%
State of Wisconsin Investment Board
56
State of Wisconsin Investment Board
Wisconsin
$271K +$7.02K +300 +3%
SIM
57
Spark Investment Management
New York
$268K +$279K +11,900 New
WCM
58
Weld Capital Management
New York
$262K +$272K +11,616 New
UBS Group
59
UBS Group
Switzerland
$243K +$68.5K +2,927 +37%
SO
60
STRS Ohio
Ohio
$239K -$178K -7,600 -42%
Manulife (Manufacturers Life Insurance)
61
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$230K +$239K +10,210 New
Barclays
62
Barclays
United Kingdom
$216K -$11.3K -482 -5%
AIG
63
American International Group
New York
$212K +$88.6K +3,786 +68%
DTL
64
Dynamic Technology Lab
Singapore
$207K +$215K +9,174 New
Morgan Stanley
65
Morgan Stanley
New York
$177K +$126K +5,366 +215%
MIM
66
MetLife Investment Management
New Jersey
$171K +$177K +7,563 New
JP Morgan Chase
67
JP Morgan Chase
New York
$95K +$44.8K +1,913 +89%
TRCT
68
Tower Research Capital (TRC)
New York
$64K +$67K +2,863 New
Legal & General Group
69
Legal & General Group
United Kingdom
$62K +$26.6K +1,137 +69%
Canada Life
70
Canada Life
Manitoba, Canada
$56K
GWM
71
Geneos Wealth Management
Colorado
$43K +$12.9K +550 +40%
AP
72
Atwood & Palmer
Missouri
$41K
AIP
73
Ameritas Investment Partners
Nebraska
$29K +$13.5K +575 +82%
Bank of Montreal
74
Bank of Montreal
Ontario, Canada
$28K +$28.6K +1,223 New
MLICM
75
Metropolitan Life Insurance Company (MetLife)
New York
$26.9K +$27.9K +1,193 New

DCPH Hedge Fund Activity: Q2 2019 in Review

85 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2019, worth a combined $522M — up 0.01% from $522M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DCPH positions and 11 closed out — a net gain of 7 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was Redmile Group, adding an estimated $13.9M. The largest seller was AllianceBernstein, cutting an estimated $11.6M.

  • 85 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2019, up from 80 in Q1 2019.
  • Funds reported $522M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 0.01% quarter-over-quarter.
  • 18 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of +7 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Redmile Group, an estimated $13.9M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was AllianceBernstein, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2019.